← All trials
NCT04914767
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Oct 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Jun 7, 2021
- Last posted
- Jun 7, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hôpital Universitaire SahloulLead sponsor
- Hôpital Universitaire SahloulReponsible party - principal investigator
- Hôpital Universitaire SahloulOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.